How gut bacteria educate our immune system and how cancer drugs can be remote-controlled

Physician and immunologist Dennis L. Kasper (81) of Harvard Medical School will receive the Paul Ehrlich and Ludwig Darmstaedter Prize 2024, endowed with €120,000, in a ceremony held in Frankfurt’s Paulskirche today. The award recognizes his discovery of the first words of the biochemical language through which bacteria that populate our colon educate our immune system, thereby ensuring its healthy development. The Early Career Award goes to chemist Johannes Karges (31) from Ruhr University Bochum for his invention of a process with which highly effective chemotherapeutic agents can only accumulate in the tumor and can only be activated there by irradiation with light or ultrasound.

Leading immunologist Dr. Dennis L. Kasper, will be awarded the Paul Ehrlich and Ludwig Darmstaedter Prize for his revolutionary discovery on gut bacteria’s role in maintaining our immune health. Meanwhile, chemist Johannes Karges received recognition for designing an innovative chemo-process activated specifically at tumor locations using light or ultrasound.

Originamitteilung:

Physician and immunologist Dennis L. Kasper (81) of Harvard Medical School will receive the Paul Ehrlich and Ludwig Darmstaedter Prize 2024, endowed with €120,000, in a ceremony held in Frankfurt’s Paulskirche today. The award recognizes his discovery of the first words of the biochemical language through which bacteria that populate our colon educate our immune system, thereby ensuring its healthy development. The Early Career Award goes to chemist Johannes Karges (31) from Ruhr University Bochum for his invention of a process with which highly effective chemotherapeutic agents can only accumulate in the tumor and can only be activated there by irradiation with light or ultrasound.

share this recipe:
Facebook
Twitter
Pinterest

Weitere spannende Artikel

ERC Consolidator Grant für Georg Winter gibt rasant wachsendem Forschungsfeld weiteren Auftrieb

Dezember 3, 2024

Maßgeschneiderte kleine Moleküle, die sich an Krebs verursachende Proteine heften und Tumorzellen dadurch unschädlich machen – das ist Georg Winters Spezialgebiet, in dem sich der Forschungsgruppenleiter am CeMM der ÖAW als weltweit führender Experten etabliert hat. Sein neuestes ERC CoG Projekt GENEomorph hebt seine Forschung auf eine neue Ebene: Anstatt Krebsproteine wie bisher für die zelluläre Müllabfuhr zu markieren, nimmt Winter mit seinen Design-Molekülen nun sogenannte Transkriptionsfaktoren ins Visier, ein vielversprechender Weg für neue Medikamente. Das sieht auch der Europäische Forschungsrat ERC so: Er fördert dieses Projekt in den nächsten fünf Jahren mit 1,9 Millionen Euro.

Read More